CA
NZ
UK
AU
IND
US
U.S. equities look set for a firmer start on Wednesday morning rather than a flat one. As of 12:11 UTC, premarket ETF proxies were higher across the board, with SPY up 0.79%,QQQup 1.28%, and DIA up 0.69%. That early strength comes after another strong …
In geopolitical brinkmanship, timing is often more consequential than firepower. President Donald Trump's decision to launch and then suspend Project Freedom within a single day illustrates precisely that calculus. What began as a high-profile naval operation to reopen the Strait of Hormuz ended as …
With AMD and Arista both beating expectations after Tuesday's close, markets open Wednesday in a risk-on posture, but the ADP employment print at 8:15 a.m. ET will test whether the labour market is holding ahead of Friday's nonfarm payrolls. Walt Disney and AppLovin report …
The US equity market session on May 5, 2026, was characterized by a powerful "risk-on" rally led squarely by the Technology sector. Unlike recent sessions defined by defensive rotations and hard-asset inflation hedges, capital flowed back into historical growth engines and beaten-down cyclical value. …
The US equity market session on May 5, 2026, presented a textbook example of the divergence between absolute price action and relative momentum. While the daily tape was dominated by a massive "risk-on" rally led by Information Technology, the Relative Rotation Graph (RRG) paints …
On the surface, the most newsworthy item surrounding Edgewise Therapeutics on Tuesday was a significant insider sale. Chief Medical Officer Joanne M. Donovan disclosed the sale of 55,230 shares across two transactions — 5,230 shares at $31.29 on May 4 and a much larger …
To appreciate why Fate Therapeutics shares surged 31% to $2.36 on Tuesday, it is necessary to understand what the FDA's CMC Development and Readiness Pilot Program actually represents — and why selection is a far more meaningful event than its understated name suggests.
Biodesix delivered a first-quarter 2026 earnings report that, by any measure, represents a genuine commercial inflection for the lung diagnostics company. Revenue of $25.6 million grew 42% year over year — a growth rate that is exceptional for a commercial-stage diagnostics business and reflects …
To understand why the EMANATE miss matters — and why it doesn't necessarily spell the end of the road — you need to understand what Setmelanotide is and what Rhythm has been trying to build with it.
Trend Structure: Transition from Consolidation to UptrendGSIT is shifting from a prolonged consolidation phase into a potential uptrend.Key observations include:• Prior distribution phase between 6–10 has stabilized• Formation of higher lows since February• Early signs of trend reversal emerging
Please wait processing your request...